Jade Biosciences, Inc. Number of Reportable Segments
Jade Biosciences, Inc. (JBIO) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-10
- Jade Biosciences, Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment.
- Jade Biosciences, Inc. number of reportable segments for fiscal 2024 was 1.00 segment.
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 12 month |
|---|---|---|
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-04-25 | |
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-27 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-06 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |